SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation

M Morelli, S Madonna, C Albanesi - Frontiers in Immunology, 2024 - frontiersin.org
SOCS are a family of negative inhibitors of the molecular cascades induced by cytokines,
growth factors and hormones. At molecular level, SOCS proteins inhibit the kinase activity of …

Autism spectrum disorder and a possible role of anti-inflammatory treatments: experience in the pediatric allergy/immunology clinic

H Jyonouchi - Frontiers in Psychiatry, 2024 - frontiersin.org
Autism spectrum disorder (ASD1) is a behaviorally defined syndrome encompassing a
markedly heterogeneous patient population. Many ASD subjects fail to respond to the 1st …

Extrapolation of upadacitinib efficacy in juvenile idiopathic arthritis leveraging pharmacokinetics, exposure–response models, and real‐world patient data

Y Qian, L Schlachter, D Eckert… - Clinical …, 2024 - Wiley Online Library
Juvenile idiopathic arthritis (JIA) is the most prevalent pediatric rheumatic disease. While
disease‐modifying antirheumatic drugs (DMARDs), especially biologics, have greatly …

Neutrophil diversity and function in health and disease

F Zhang, Y Xia, J Su, F Quan, H Zhou, Q Li… - … and Targeted Therapy, 2024 - nature.com
Neutrophils, the most abundant type of granulocyte, are widely recognized as one of the
pivotal contributors to the acute inflammatory response. Initially, neutrophils were …

Case report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behçet's disease

S Sha, B Xu, K Wang, C Qiao, H Shi, J Jiang… - Frontiers in …, 2024 - frontiersin.org
Background The limited therapeutic options and inconsistent treatment efficacy of Intestinal
Behçet's disease complicate its management, with the absence of standardized guidelines …

Pregnancy outcomes in patients treated with upadacitinib: analysis of data from clinical trials and postmarketing reports

U Mahadevan, G Levy, L Gensler, M Ali, AP Lacerda… - Drug Safety, 2024 - Springer
Abstract Background and Objective Upadacitinib is indicated for diseases affecting persons
of childbearing potential including rheumatoid arthritis, psoriatic arthritis, axial …

Pharmacokinetics, safety, tolerability, and exploratory efficacy of Upadacitinib in children with severe atopic dermatitis

Y Qian, EM Raymundo, S Hao, K Unnebrink… - Clinical Therapeutics, 2024 - Elsevier
Purpose This study aims to characterize the pharmacokinetics, safety, tolerability, and
exploratory efficacy of upadacitinib, an oral Janus kinase inhibitor approved for treating …

Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature

AR Furtunescu, SR Georgescu, M Tampa… - International Journal of …, 2024 - mdpi.com
Psoriasis is a highly prevalent dermatological disease associated with an increased
systemic inflammatory response. In addition, joint involvement is also present in around 20 …

Current and emerging drugs for the treatment of pruritus: an update of the literature

RH Mahmoud, SG Brooks… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Pruritus, particularly in its chronic form, often imposes significant suffering and
reductions in patients' quality of life. The pathophysiology of itch is varied depending on …

Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management

AM Caballero-Mateos… - World Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
Recent advancements in the treatment landscape of ulcerative colitis (UC) have ushered in
a new era of possibilities, particularly with the introduction of Janus kinase (JAK)-signal …